Documents tabled in the Senate today raised serious questions about the information provided on PBAC deferrals at Senate Estimates. The advice to Mark Butler indicates the committee's chair may have been indirectly involved in formulating the plan, that the department is legally required to evaluate submissions lodged for March regardless of capacity constraints, and that officials did not consult the industry as directed.
Publication of ministerial advice raises questions about the evidence given at Senate Estimates
November 29, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News

